Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

bupivacaine

EXPAREL LIPOSOMAL

bupivacaine (EXPAREL LIPOSOMAL) is a sodium channel protein type iv alpha subunit blocker. Associated with Pacira Ireland Limited. Route of administration: periarticular. Current US regulatory status: approved.

FDA: approved EMA: approved NMPA: clinical trials Nervous system (N01) N01BB01
US status approved
Patents linked 20
Pipeline programs 80
News articles 0
Drug details — bupivacaine
US status
approved
Class
Nervous system (N01)
Route
PERIARTICULAR
Patents
20
Programs
80
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

bupivacaine (EXPAREL LIPOSOMAL) is a sodium channel protein type iv alpha subunit blocker. Associated with Pacira Ireland Limited. Route of administration: periarticular. Current US regulatory status: approved.

Key facts

INN bupivacaine
Brand EXPAREL LIPOSOMAL
Mechanism Sodium channel protein type IV alpha subunit blocker
Target Sodium channel protein type 4 subunit alpha
Therapeutic class Nervous system (N01)
Route PERIARTICULAR
Formulation INJECTABLE, LIPOSOMAL
ATC code N01BB01
Originator Pacira Ireland Limited

Mechanism of action

Sodium channel protein type IV alpha subunit blocker

Primary target: Sodium channel protein type 4 subunit alpha

Approval history

Authority Status Date
FDA approved —
EMA approved —
NMPA clinical trials —

Pipeline programs

Search pipeline Sponsor programs
  1. Bupivacaine Phase 3 · Pacira Ireland · Malignant Neoplasms of Female Genital Organs
  2. Bupivacaine Phase 3 · United Therapeutics Europe · Postoperative Pain
  3. Bupivacaine HCl Phase 3 · Pacira Ireland · Hemorrhoids
  4. Bupivacaine HCl Phase 3 · Pacira Ireland · Postoperative Pain
  5. Bupivacaine Liposome Injection Phase 3 · United Therapeutics Europe · Osteoarthritis
  6. Bupivacaine liposome Phase 3 · Pacira Ireland · Dental Pain
  7. Bupivacaine liposome injectable suspension 266 mg Phase 3 · Pacira Ireland · Bunionectomy
  8. EXPAREL Phase 3 · Pacira Ireland · Total Ankle Arthroplasty

Related & competitor drugs

Browse all drugs
  1. aripiprazole Nervous system (N05)
  2. brexpiprazole Nervous system (N05)
  3. brivaracetam Nervous system (N03)
  4. bupivacaine hydrochloride Sodium channel protein type IV alpha subunit blocker
  5. buprenorphine Nervous system (N07)
  6. caffeine citrate Nervous system (N06)

Related patents

Browse patents Pacira Ireland Limited patent hub

  1. US 12370142

    Manufacturing of bupivacaine multivesicular liposomes

    Expires 2045-07-24T00:00:00.000Z

    granted

  2. US 12364764

    Sustained release thermosetting gels comprising sodium channel blockers and the methods of making same

    Expires 2045-07-17T00:00:00.000Z

    granted

  3. US 12318483

    Manufacturing of bupivacaine multivesicular liposomes

    Expires 2045-05-29T00:00:00.000Z

    granted

  4. US 12296047

    Manufacturing of bupivacaine multivesicular liposomes

    Expires 2045-05-08T00:00:00.000Z

    granted

  5. US 12285419

    Bupivacaine multivesicular liposome formulations and uses thereof

    Expires 2045-04-24T00:00:00.000Z

    granted

  6. US 12280149

    Manufacturing of bupivacaine multivesicular liposomes

    Expires 2045-04-17T00:00:00.000Z

    granted

  7. US 12251472

    Manufacturing of bupivacaine multivesicular liposomes

    Expires 2045-03-13T00:00:00.000Z

    granted

  8. US 12251468

    Manufacturing of bupivacaine multivesicular liposomes

    Expires 2045-03-13T00:00:00.000Z

    granted

  9. US 12246092

    Manufacturing of bupivacaine multivesicular liposomes

    Expires 2045-03-06T00:00:00.000Z

    granted

  10. US 12226610

    Treatment of pain associated with total knee arthroplasty with sustained-release liposomal anesthetic compositions

    Expires 2045-02-13T00:00:00.000Z

    granted

  11. US 12178909

    Manufacturing of bupivacaine multivesicular liposomes

    Expires 2044-12-26T00:00:00.000Z

    granted

  12. US 12156940

    Manufacturing of bupivacaine multivesicular liposomes

    Expires 2044-11-28T00:00:00.000Z

    granted

  13. US 12151024

    Manufacturing of bupivacaine multivesicular liposomes

    Expires 2044-11-21T00:00:00.000Z

    granted

  14. US 12144890

    Manufacturing of bupivacaine multivesicular liposomes

    Expires 2044-11-14T00:00:00.000Z

    granted

  15. US 11931459

    Treatment of pain in pediatric patients by administration of sustained-release liposomal anesthetic compositions

    Expires 2044-03-14T00:00:00.000Z

    granted

  16. US 11925706

    Manufacturing of bupivacaine multivesicular liposomes

    Expires 2044-03-07T00:00:00.000Z

    granted

  17. US 11918565

    Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions

    Expires 2044-02-29T00:00:00.000Z

    granted

  18. US 11844837

    Compositions of a polyorthoester and an organic acid excipient

    Expires 2043-12-14T00:00:00.000Z

    granted

  19. US 11819575

    Manufacturing of bupivacaine multivesicular liposomes

    Expires 2043-11-16T00:00:00.000Z

    granted

  20. US 11819574

    Manufacturing of bupivacaine multivesicular liposomes

    Expires 2043-11-16T00:00:00.000Z

    granted

Frequently asked questions

What is bupivacaine?

bupivacaine (EXPAREL LIPOSOMAL) is a sodium channel protein type iv alpha subunit blocker. Associated with Pacira Ireland Limited. Route of administration: periarticular. Current US regulatory status: approved.

What is the brand name for bupivacaine?

EXPAREL LIPOSOMAL is a marketed brand name for bupivacaine. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of bupivacaine?

bupivacaine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.